シンバイオ製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/01/28 | 1,005 | 1,007 | 984 | 996 | +6 | +0.6% | 642,500 |
2022/01/27 | 1,033 | 1,042 | 985 | 990 | -45 | -4.3% | 1,150,300 |
2022/01/26 | 998 | 1,043 | 997 | 1,035 | +44 | +4.4% | 917,000 |
2022/01/25 | 1,034 | 1,045 | 991 | 991 | -45 | -4.3% | 1,027,200 |
2022/01/24 | 1,003 | 1,037 | 996 | 1,036 | +15 | +1.5% | 601,300 |
2022/01/21 | 1,023 | 1,042 | 995 | 1,021 | -13 | -1.3% | 852,600 |
2022/01/20 | 997 | 1,041 | 995 | 1,034 | +25 | +2.5% | 787,100 |
2022/01/19 | 1,026 | 1,037 | 997 | 1,009 | -34 | -3.3% | 1,178,200 |
2022/01/18 | 1,043 | 1,089 | 1,032 | 1,043 | +8 | +0.8% | 914,800 |
2022/01/17 | 1,075 | 1,081 | 1,035 | 1,035 | -41 | -3.8% | 589,500 |
2022/01/14 | 1,081 | 1,091 | 1,066 | 1,076 | -25 | -2.3% | 924,000 |
2022/01/13 | 1,107 | 1,126 | 1,091 | 1,101 | -13 | -1.2% | 654,600 |
2022/01/12 | 1,095 | 1,125 | 1,091 | 1,114 | +38 | +3.5% | 1,264,800 |
2022/01/11 | 1,036 | 1,087 | 1,032 | 1,076 | +35 | +3.4% | 1,184,300 |
2022/01/07 | 1,075 | 1,084 | 1,027 | 1,041 | -30 | -2.8% | 1,078,500 |
2022/01/06 | 1,075 | 1,104 | 1,068 | 1,071 | -33 | -3% | 1,100,100 |
2022/01/05 | 1,155 | 1,155 | 1,094 | 1,104 | -54 | -4.7% | 1,368,400 |
2022/01/04 | 1,150 | 1,166 | 1,125 | 1,158 | +13 | +1.1% | 926,400 |
2021/12/30 | 1,127 | 1,152 | 1,107 | 1,145 | +4 | +0.4% | 966,900 |
2021/12/29 | 1,087 | 1,147 | 1,085 | 1,141 | +52 | +4.8% | 1,365,600 |
2021/12/28 | 1,118 | 1,122 | 1,070 | 1,089 | -21 | -1.9% | 1,314,500 |
2021/12/27 | 1,141 | 1,145 | 1,106 | 1,110 | -33 | -2.9% | 1,238,300 |
2021/12/24 | 1,145 | 1,173 | 1,137 | 1,143 | +6 | +0.5% | 1,103,000 |
2021/12/23 | 1,152 | 1,155 | 1,123 | 1,137 | -4 | -0.4% | 773,200 |
2021/12/22 | 1,121 | 1,157 | 1,104 | 1,141 | +25 | +2.2% | 1,209,100 |
2021/12/21 | 1,134 | 1,137 | 1,090 | 1,116 | +15 | +1.4% | 1,191,000 |
2021/12/20 | 1,160 | 1,186 | 1,100 | 1,101 | -80 | -6.8% | 1,696,100 |
2021/12/17 | 1,180 | 1,205 | 1,164 | 1,181 | -19 | -1.6% | 1,248,500 |
2021/12/16 | 1,198 | 1,210 | 1,168 | 1,200 | +30 | +2.6% | 1,309,700 |
2021/12/15 | 1,134 | 1,189 | 1,133 | 1,170 | +22 | +1.9% | 1,150,000 |
2021/12/14 | 1,143 | 1,183 | 1,139 | 1,148 | -11 | -0.9% | 979,400 |
2021/12/13 | 1,190 | 1,194 | 1,138 | 1,159 | -21 | -1.8% | 1,434,400 |
2021/12/10 | 1,196 | 1,213 | 1,166 | 1,180 | -20 | -1.7% | 1,684,300 |
2021/12/09 | 1,261 | 1,285 | 1,194 | 1,200 | -91 | -7% | 3,136,400 |
2021/12/08 | 1,206 | 1,299 | 1,200 | 1,291 | +89 | +7.4% | 2,820,400 |
2021/12/07 | 1,197 | 1,227 | 1,170 | 1,202 | +61 | +5.3% | 2,181,100 |
2021/12/06 | 1,200 | 1,210 | 1,131 | 1,141 | -95 | -7.7% | 2,476,500 |
2021/12/03 | 1,190 | 1,273 | 1,171 | 1,236 | +60 | +5.1% | 3,976,300 |
2021/12/02 | 1,235 | 1,253 | 1,159 | 1,176 | -67 | -5.4% | 2,585,000 |
2021/12/01 | 1,320 | 1,340 | 1,187 | 1,243 | -61 | -4.7% | 3,230,000 |
2021/11/30 | 1,416 | 1,440 | 1,292 | 1,304 | -94 | -6.7% | 3,455,700 |
2021/11/29 | 1,403 | 1,467 | 1,380 | 1,398 | -79 | -5.3% | 3,607,700 |
2021/11/26 | 1,585 | 1,608 | 1,445 | 1,477 | -87 | -5.6% | 3,319,100 |
2021/11/25 | 1,758 | 1,758 | 1,460 | 1,564 | -193 | -11% | 6,600,600 |
2021/11/24 | 1,782 | 1,852 | 1,755 | 1,757 | -24 | -1.3% | 5,375,200 |
2021/11/22 | 1,750 | 1,888 | 1,718 | 1,781 | +7 | +0.4% | 8,743,700 |
2021/11/19 | 1,789 | 1,813 | 1,724 | 1,774 | -26 | -1.4% | 4,795,700 |
2021/11/18 | 1,791 | 1,867 | 1,701 | 1,800 | +99 | +5.8% | 14,659,900 |
2021/11/17 | 1,429 | 1,701 | 1,418 | 1,701 | +300 | +21.4% | 12,563,100 |
2021/11/16 | 1,490 | 1,610 | 1,362 | 1,401 | +54 | +4% | 15,079,300 |
801~
850
件表示中 / 3314件
類似銘柄と比較する
現在ご覧いただいている「シンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
シンバイオ | 15,500円 | -24.2% | - | 0.00% | - | 1.95倍 |
|
導入で新薬開発・製品化。抗がん剤「トレアキシン」国内販売。抗ウイルス薬BCVの開発に注力 |
ケイファーマ | 74,300円 | - | - | 0.00% | - | 3.82倍 |
|
慶応大学発ベンチャー。iPS細胞による再生医療と創薬の2本柱。中枢神経系が得意領域 |
サイフューズ | 97,200円 | +459.3% | - | 0.00% | - | 3.24倍 |
|
バイオ3Dプリンタを開発、自家細胞製品の製造受託も。臓器など再生医療等製品を臨床開発中 |
ソレイジア | 3,300円 | +311.4% | - | 0.00% | - | 6.23倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
日ケミファ | 153,000円 | +2.5% | - | 3.27% | 92.00倍 | 0.30倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
市場注目の銘柄
チャート関連のコラム